Jonas Salk laboratory. He later joined the National Foundation for Infantile Paralysis's polio project established by President Franklin D. Roosevelt. Extensive publicity and fear of polio led to much increased funding, $67 million by 1955, but research continued on dangerous live vaccines. Salk decided to use the safer 'killed' virus, instead of weakened forms of strains of polio viruses like the ones used contemporarily by Albert Sabin, who was developing an oral vaccine. After successful tests on laboratory animals, on July 2, 1952, assisted by the staff at the D.T. Watson Home for Crippled Children, Salk injected 43 children with his killed-virus
Remune P < 0.05 & HIV-1 lymphocyte proliferation P < 0.001 both favoring the Remune Group. The International AIDS Vaccine Research (IAVA) issued a report on “Whole Killed AIDS Vaccines” in 1999 reviewing a diverse aspect of the killed virus approach. Remune Remune is the first therapeutic HIV vaccine based on the killed whole virus approach. Remune was initially invented by Jonas Salk in 1987 and is now being developed by Immune Response BioPharma, Inc. (IRBP) Remune is a therapeutic HIV/AIDS vaccine that has completed over 25 clinical studies to date and shows a robust mechanism of action restoring white blood